Key result
IV iron reduces NT-proBNP ~74% and CRP vs placebo in anemic CHF with renal insufficiency.
Why the study?
Chronic heart failure and chronic renal failure associated with iron deficiency anemia is a common problem linked to inflammation, prompting evaluation of whether intravenous iron therapy without erythropoietin modifies NT-proBNP, CRP, and clinical parameters.
Comparison
Iron sucrose complex (200 mg weekly for 5 weeks) vs isotonic saline solution
Design
Double-blind randomized placebo-controlled study
Follow-up
6 months
Authors
Loading...
Supports IV iron consideration in anemic HF with renal insufficiency; extends evidence for iron repletion in comorbid HF.
RCT (n=40)
Double-blind
randomized
Absolute Event Rate: 117.5% vs 450.9%
p-value: p=< 0.01
Toblli et al. (2007) conducted an RCT in Chronic heart failure and chronic renal failure with anemia (n=40). Intravenous iron sucrose complex vs. Placebo (isotonic saline solution) was evaluated on NT-proBNP levels at 6 months (pg/ml) (p=< 0.01). Intravenous iron therapy significantly reduced NT-proBNP (117.5 vs 450.9 pg/ml, p<0.01) and CRP levels compared to placebo in anemic patients with chronic heart failure and renal insufficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: